Liberty Biopharma Announces the Appointment of Dr. Hon-Kan Yip as Medical Advisor
October 20, 2016 - Richmond, British Columbia: Liberty Biopharma Inc. ("Liberty" or "Company") is pleased to announce the appointment of Dr. Hon-Kan Yip, MD, as medical advisor.
Dr. Yip is a clinical specialist for interventional cardiology at Chang Gung Memorial Hospital - Kaohsiung Medical Centre in Taiwan. He is a leading researcher in the field of translational (clinical application) medicine, which includes the use of regenerative cells for cardiovascular diseases and inflammation. Dr. Yip is a clinical professor with Chang Gung Medical Institute and has authored over 185 research publications in leading international journals.
Dr. Yip is conducting research projects with our bioprocessing system to isolate adipose derived stromal vascular fraction, which contains regenerative cells and stem cells, for the promotion of wound healing and study its effect on acute myocardial infarction (e.g. heart attack) and acute ischemic diseases (e.g. stroke).
"Dr. Yip's extensive portfolio of international research publications in translational medicine and his expertise in cardiovascular diseases, will provide valuable guidance for the advancement of other clinical applications" stated Dr. Peter Neweduk, CEO of Liberty. "We are delighted to welcome Dr. Hon-Kan Yip to our Medical Advisory Committee"
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "likely", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
For further information, please contact:
Liberty Biopharma Inc.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 604-377-7575
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly